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Abstract

Clostridium Difficile Infection (CDI) has registered a dramatically increasing incidence in the
general population over the past decades. Nowadays, Clostridium Difficile is the leading cause of
hospital-acquired diarrhea in Europe and North America. Liver cirrhosis is the final stage of any
chronic liver disease (CLD). The most common causes are chronic hepatitis C or B and viral coinfections, alcohol misuse, and nonalcoholic fatty liver disease (NAFLD).
CLD and cirrhosis are listed among the ten leading causes of death in the US. Cirrhosis due to
any etiology disrupts the homeostatic role of the liver in the body. Cirrhosis-associated immune
dysfunction (CAID) leads to alterations in both inherited and acquired systemic and local liver
immunity. CAID is caused by increased systemic inflammation and immunodeficiency and it is
responsible for 30% of mortality rates all over the world.
Clostridium Difficile infection frequently affects patients suffering from liver cirrhosis because
of the high number of prolonged hospitalizations, regular use of antibiotics for the prevention or
treatment of SBP, proton pump inhibitor (PPI) use, and an overall immunocompromised state.
Clostridium Difficile is a Gram-positive bacterium responsible for the high morbidity and mortality
rates in patients with cirrhosis, with an essential increase in a 30-day mortality.
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Highlights

✓ Patients with liver cirrhosis are characterized by alterations of inherited and acquired
immunosuppression, being an easy target for Clostridium Difficile, which is associated
with significant morbidity and mortality.

clostridium difficile, liver cirrhosis, anaerobic infection, immune dysfunction

✓ The latest guideline treatment recommendations for an initial episode of Clostridium
Difficile have changed, either vancomycin or fidaxomicin now currently chosen over
metronidazole.
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Introduction

Discussions

Clostridium Difficile represents a common infection in
healthcare settings, being responsible for severe diarrhea
(1-3). Hall and O'Toole first isolated C. Difficile from the
stool of a healthy infant. The given name of the bacterium

The highest incidence is among those aged over 65

Pathogenesis
Clostridium Difficile is an anaerobic, Gram-positive,
spore-forming bacillus, which may be part of the normal
intestinal microbiota in healthy newborns. The
microorganism, first described in 1935, is transmitted
through the oral-fecal route. CDI affects tissues through
toxin production. The pathogenesis strains of C. Difficile
produce two exotoxins: A (enterotoxin) and B (cytotoxin).
The pathogenic effect involves several steps. Before
toxin production, which is essential for gut damage and
diarrhea occurrence, the germination of C. Difficile spores
is required. The survival in spore formula provides

years, being more prevalent among females and whites.
Clostridium Difficile is the most common pathogen in
nosocomial and antibiotic-associated diarrheal diseases. It
can also be a community-acquired Clostridium Difficile
infection in patients with no risk factors (5). The frequency
of the Clostridium Difficile infection (CDI) and its
increased morbidity, which is associated with a prolonged

resistance to antibiotics and is responsible for recurrent
disease following the eradication treatment (12-14).
The lumen of the colon is anoxic, thus creating the
perfect environment for anaerobic bacteria such as
Clostridium Difficile to survive and moreover, to
proliferate and produce toxins. The bacterial spores resist
against oxygen, heat, and common ethanol-based

duration of treatment, leads to a significant increase in
hospital treatment costs.

disinfectants, which favor proliferation (15).
Many efforts have been made throughout the years to
understand Clostridium Difficile sporulation, but
understanding is still currently limited. Commonly, C.
Difficile acts like a nosocomial pathogen, the source of
infection being contaminated by humans or healthcare

resulted from the difficulty of isolation and culture by
using the available methods at the time. The secondary
pseudomembranous colitis associated with C. Difficile
infection was first described in 1893. In 1978, researchers
associated C. difficile with antibiotic-associated diarrhea
(4).

Cirrhosis occurs when regenerative nodules surrounded
by fibrous bands replace the healthy liver tissue. This
deranged histologic architecture is responsible for the
portal hypertension and end-stage liver disease. The cause
of cirrhosis is easy to recognize by making a minute history
anamnesis, and also by combining the serologic and
histologic evaluation. According to the geographic area,
the leading cause responsible for the occurrence of liver
cirrhosis is different. For example, abusive alcohol intake
and hepatitis C infection are the most common causes of
liver cirrhosis in developed countries, while hepatitis B is
common in endemic areas such as Asia and sub-Saharan

facilities. Spores are resistant to gastric acidity and
germinate into the vegetative form in the intestine.
Hospitalized patients may acquire CDI by the ingestion of
spores or vegetative bacteria from the environment or the
hands of healthcare personnel (16).
Liver cirrhosis is a progressive disease, evolving from
an asymptomatic, compensated stage to a complicated,

Africa. Nonalcoholic steatohepatitis (NASH) in obese and
diabetic patients is responsible for the development of liver
cirrhosis when there is no other apparent cause. Knowing
the etiology is essential in order to apply the correct
treatment and to predict both evolution and prognosis (69).

decompensated one, usually associated with poor
prognosis. Any type of infection can decompensate a
compensated liver cirrhosis and lead to complications of
cirrhosis such as upper digestive bleeding, ascites,
hepatorenal or hepatopulmonary syndrome, or hepatic
encephalopathy, all of which have high mortality rates.
Regardless of its etiology, cirrhosis, as the end stage of

The Clostridium Difficile infection is becoming an
increasingly incident disease, with the highest risk of

chronic liver disease, commonly evolves to a syndrome
called cirrhosis-associated immune dysfunction syndrome

infection occurring in hospitalized patients and with
unusually high mortality in immunosuppressed patients,
responsible for high morbidity and mortality rates, being

(CAIDS). Abnormalities of the immune function in
patients with liver cirrhosis are caused by the
immunodeficiency and systemic inflammation that occur

a substantial financial burden for healthcare providers
(10, 11).

in cirrhosis. The syndrome of decreased immunity is a
combination of different immunological mechanisms and
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reactions which result from an advanced stage of the liver
disease (17, 18). The local impaired immune response is
responsible for not recognizing antigens; in this way, the
effector mechanisms are improper (19). An imbalance
between the pro-inflammatory and anti-inflammatory
mechanisms occurs and the activation of the immune
system is inefficient (20, 21).
Clinical entities such as pneumonia, spontaneous
peritonitis, skin inflammatory diseases, infections of the
urinary system, fungal infections, and C. Difficile diarrhea
should be promptly recognized and treated (22-24). By
adopting this approach, the risk of complications decreases
and both prognosis and outcome can be improved (25, 26).
Risk factors
Cirrhotic patients represent a particular category of
patients, their disease carrying many potential risk factors
for the development of CDI, especially in decompensated
stages of the illness (27, 28). Clostridium Difficile
infection has an increased prevalence as a second infection
in cirrhotic patients.
Many studies confirm the idea that intercurrent
infections in patients with liver cirrhosis, especially in
advanced stages (Child Pugh B or C), increase mortality by
4 times. One third of patients die within the first month
after the infection and another third die within the first 12
months. This category of patient is at increased risk of
developing Clostridium Difficile colitis for many reasons,
most of which can be explained briefly as follows.
The use of antibiotics remains the most widely
recognized risk factor for the development of C. Difficile
infection. Cirrhotic patients often require prophylactic or
curative antibiotic therapy, for example Norfloxacin,
which is commonly used in the outpatient prophylaxis of
spontaneous bacterial peritonitis (SBP), and quinolones or
third-generation cephalosporins used in case of upper
digestive bleeding. Also, these patients are more frequently
cared for in an intensive care unit (ICU) and antibiotics are
prescribed during their hospitalization (5).
Almost all antibiotics can disrupt the normal gut
microbiota, allowing Clostridium Difficile to spread and
produce toxins. The risk of infection is increased directly
proportional to the duration and quantity of antibiotics
administered, but cases of infection have been reported
even after a single dose administration (29).
Rifaximin is a routine medication in the prevention of
hepatic encephalopathy, as well as Lactulose. Rifaximin
has a broad antimicrobial spectrum, including aerobes and
anaerobes, Gram-positive and Gram-negative bacteria.
According to literature data, when administered orally, 400

mg twice per day, 10 days a month, it seems to be useful in
C. Difficile infection as well, because it is virtually nonabsorbed and its activity occurs mostly within the intestinal
lumen (30). Recent studies have revealed that both
Rifaximin and Lactulose are associated with a reduced risk
of developing CDI in hospitalized patients, whether or not
they received other antibiotics. This phenomenon could be
possible due to the fact that Lactulose reduces the
production of short chain fatty acids and Rifaximin
suppresses the enteral ammonia, with those effects having
a protective effect by reducing the suitable conditions for
Clostridium Difficile proliferation (31). However,
resistance was noted. There are few studies regarding the
risk of developing CDI in cirrhotic patients receiving
Rifaximin, so clinicians should also be aware of this risk.
Other potential risk factors in cirrhotic patients could
be frequent and prolonged hospitalization periods which
place the patient in a suitable environment for high
exposure to CDI, proton pump inhibitors (PPI) utilization
for peptic ulcers, ligation-induced ulcers or
gastroesophageal reflux, advanced age associated with a
multitude of comorbidities, malnutrition, cancer, antiviral
treatments, and the overall immunocompromised state. As
an observation, C. Difficile infections were more
frequently detected in patients with alcoholic liver cirrhosis
(32, 33).
C. Difficile infections in patients with liver cirrhosis
worsen the disease outcome; however, the overall mortality
is not affected if appropriate diagnosis is made and suitable
treatments are applied (34). Severe hypoalbuminemia and
intensive care admission are predictors of increased
mortality in cirrhotic patients with C. Difficile infection
(11, 13).
Treatment
The diagnosis of C. Difficile infection takes into
account clinical manifestations such as diarrhea - Bristol
stool chart types 5–7, meaning more than three stools
within 24 hours, accompanied by abdominal pain and
systemic signs and symptoms such as fever, hypotension,
or shock, but also a positive result of C. Difficile and/or its
toxins in laboratory testing. Antibiotic therapy is the first
choice for CDI, and specific guideline recommendations
are based on the severity of the disease.
The latest guideline treatment recommendation for an
initial episode of mild to moderate Clostridium Difficile
infection has changed, recent data suggesting an overall
superiority of vancomycin over metronidazole. The oral
formula of vancomycin in dosages of 125 mg four times
per 24 hours for 10–14 days is preferred. In case of
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recurrence, fidaxomicin 200 mg twice a day for ten days is
preferred, but this medication is not available in Romania
(28).
For severe or fulminant cases, metronidazole 500 mg
intravenously three times a day for 10–14 days combined
with vancomycin 125 mg orally four times a day for 10–14
days is recommended.
The first recurrence requires the same treatment as the
initial episode, but for the second or further recurrences,
vancomycin in a pulsed regimen and fecal microbiota
transplantation (FMB) are recommended (21).
Fecal microbiota transplantation for an initial episode
has not yet been sufficiently studied, but it is considered to
be the most effective, inexpensive, and quickest solution
for a recurrent infection. Despite ongoing studies, donor
selection and screening, along with timing and route of
transplantation remain important issues regarding FMB
(35).
A unified standard to screen donors is not available at
the moment. Summarized donor criteria include being able
to give written consent, being over 18 years or parental
consent and child assent in the case of minors. The
exclusion criteria are: drug use, history of incarceration,
history of chronic gastrointestinal disease, autoimmune,
atopic diseases, chronic neurologic disorders, obesity or
severe
malnutrition,
malignancy
or
ongoing
immunosuppressive therapy/chemotherapy, and strong
family history of colorectal neoplasia; in the past 12
months: blood transfusions, unprotected intercourse, and
known interaction with HBV, HCV, HIV; in the past 6
months: tattoos, piercings, and international tropical
travels; in the past 3 months: antibiotic use and smallpox
vaccine; and in the past month: diarrhea, emesis, and fever
or family members showing signs of gastrointestinal
infection. There are both mandatory and optional blood
tests in the guidelines. The required ones are HBV surface
antigen, HCV antibody, HAV IgM, HIV 1+2, syphilis
tests; and optionally, patients could be tested for HTLV
1+2, BK virus, Epstein-Barr virus, HBV core antibody, and
HBV surface antibody. Blood tests such as complete blood
counts, liver and kidney tests could be useful, but are not
compulsory. Mandatory stool testing includes Clostridium
Difficile, and then bacterial culture for Salmonella,
Yersinia, Shigella, Campylobacter and E. Coli; parasite
and ovum examination, and additional tests depending on
the case such as Giardia, Rotavirus, Listeria spp, Vibrio
spp, Isospora, Cyclospora, Helicobacter Pylori, Entamoeba
histolytica (36, 37).
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When choosing the treatment for the C. Difficile
infection associated with liver cirrhosis, severe illness,
cachexia related to impaired protein balance, and
complications limit the treatment options and efficacy (31).

Conclusions
C. difficile is a Gram-positive bacterium living in many
resistant forms, overwhelming harsh environments and
conventional sterilization options. It is a nosocomial
pathogen, the source of infection is infected by humans and
contaminated hospital or medical devices.
Cirrhotic patients are more frequently cared for in an
intensive care unit (ICU) and they are prescribed
antibiotics during their hospitalization; spontaneous
bacterial peritonitis (SBP), prophylactic or curative
antibiotic use; the administration of antibiotics in variceal
upper digestive bleeding, all of these being particular CDI
development risk factors in patients with liver cirrhosis.
The Clostridium Difficile infection is becoming an
increasingly incident disease, with the highest risk of
infection occurring in hospitalized patients and with
unusually high mortality in immunosuppressed patients. C.
Difficile infections in patients with liver cirrhosis are
associated with a significant increase of a 30-day mortality,
but not overall mortality. Liver failure producing severe
hypoalbuminemia and ICU admissions worsen the
mortality rates and prognosis in cirrhotic patients infected
with C. Difficile. However, it is difficult to fix the mortality
rates attributable to C. Difficile infection in a group of
patients with severe comorbidities, such as the liver
cirrhosis group.
During the past decade, understanding the pathogenesis
of Clostridium Difficile infection has substantially
increased, thus leading to new therapeutic approaches.
Fecal microbiota transplantation is considered a giant step
forward, because it is indisputably effective as a curative
treatment. We thus predict that CDI could be the first
infection efficiently treated with bacteriotherapy.
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